Q1 2025 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2025-05-15 · accession 0000950123-25-005753
$1.31B
Reported value
31
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922908769 | VTI | VANGUARD INDEX FDS | $285.4M | 21.7% | 1,038,550 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $122.2M | 9.29% | 2,330,830 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $117.7M | 8.95% | 5,350,000 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $109.9M | 8.36% | 165,836 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $73.2M | 5.57% | 272,801 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $67.6M | 5.14% | 1,500,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $55.3M | 4.21% | 724,666 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $51.1M | 3.89% | 9,665,128 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $49.2M | 3.75% | 372,327 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $42.8M | 3.25% | 1,275,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $34.6M | 2.63% | 490,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $34.6M | 2.63% | 1,872,142 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $34.6M | 2.63% | 915,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $33.2M | 2.53% | 789,129 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $30.3M | 2.31% | 2,250,300 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $27.1M | 2.06% | 1,725,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $22.4M | 1.71% | 2,750,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $21.8M | 1.66% | 1,200,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $20.3M | 1.54% | 228,804 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $17.5M | 1.33% | 2,214,967 | Common | SOLE |
| 15678C102 | CBLL | CERIBELL INC | $16.9M | 1.29% | 880,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $13.7M | 1.04% | 3,000,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $7.3M | 0.56% | 1,100,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $6.3M | 0.48% | 1,950,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $3.9M | 0.30% | 1,122,581 | Common | SOLE |
| 51655R101 | — | LANZATECH GLOBAL INC | $3.8M | 0.29% | 15,814,845 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $3.7M | 0.28% | 3,354,449 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $3.6M | 0.27% | 1,850,000 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $2.5M | 0.19% | 1,126,915 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $1.8M | 0.14% | 441,558 | Common | SOLE |
| 36322Q206 | DMRA | GALECTO INC | $309,730 | 0.02% | 99,913 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.